New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

Packaging Issue Leads to Massive Pfizer Recall

As an interim measure, the company wants pharmacists to put the blister packs in child-resistant vials before giving them to patients.

Nurtec Rimegepant Receives Fda Approval For The Acute Treatment Of Migraine In Adults 722x406
Pfizer

According to a recent FiercePharma article, Pfizer is recalling 4.2 million units of its migraine therapy Nurtec ODT because its blister packaging is not child-resistant. The recall is being carried out in conjunction with the US Consumer Product Safety Commission (CPSC). No injuries have been reported, and a remedy has already been identified. Pfizer has instructed pharmacists to place the implicated blister cards in a child-resistant vial before administering it to patients. The products were sold at pharmacies across the US between December 2021 and March 2023, and were manufactured by Biohaven and Pfizer.

Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub